Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych VivasGeneral adult psychiatry — personality disorders

Psych Vivas · General adult psychiatry — personality disorders

Schizotypal personality disorder — structured clinical viva

Fellowship viva covering STPD criteria, schizophrenia and ASD differentials, conversion monitoring, limited antipsychotic evidence, comorbidity treatment, and anti-nihilism psychosocial care.

clinical
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
You are the psychiatry registrar. A 31-year-old woman with longstanding eccentric beliefs, sparse friendships, and ideas of reference is referred after her partner worries she is 'becoming schizophrenic.' She still works part-time and questions some of her referential ideas. The GP asks whether she needs an antipsychotic 'for personality' and whether her children are at risk from her oddness. Discuss diagnosis, differentials, risk formulation, treatment evidence, and communication with the GP.

Interpretation

Reveal interpretation

This presentation is most consistent with schizotypal personality disorder if a longitudinal pattern meets DSM ≥5 of 9 features with general PD criteria: cognitive-perceptual oddness (ideas of reference with residual doubt), interpersonal deficits, and eccentricity, without frank sustained psychosis. Working part-time and questioning referential ideas argue against current schizophrenia, but you must still take a full history for duration, functional trajectory, substances, depression, ASD developmental profile, and family history.[1][2]

Risk. Separate (a) suicide/self-neglect risk linked to depression and isolation from (b) conversion risk if conviction and function worsen, and (c) parenting capacity/safeguarding, which depends on functional impairment, insight, and specific behaviours — oddness alone is not automatic child removal. Assess capacity decision-specifically and act on statutory safeguarding duties when indicated without inventing foreign legal sections.[1][5]

Treatment answer to the GP. Psychotherapy/alliance-first psychosocial care is foundational. No antipsychotic is a disease-modifying “personality drug.” Time-limited low-dose antipsychotic trials may be considered for severe cognitive-perceptual distress with targets and review dates; evidence certainty is limited (Jakobsen; Kirchner; Gundersen GRADE). Treat depression/anxiety properly. Monitor conversion and escalate to early psychosis pathways if frank psychosis or UHR thresholds with decline emerge.[2][3][4][5]

Key points

Spectrum-adjacent not psychotic by default

Residual insight and preserved function distinguish STPD from current schizophrenia — still monitor conversion.[1]

No personality neuroleptic

Antipsychotics are symptom-targeted time-limited trials, not lifelong cures for eccentricity.[3][4]

Safeguarding is functional not aesthetic

Parenting risk tracks impairment, insight, and behaviour — not eccentricity per se.[1]
[2] [5]

References

  1. [1]Rosell DR, Futterman SE, McMaster A, Siever LJ Schizotypal personality disorder: a current review Curr Psychiatry Rep, 2014.PMID 24828284
  2. [2]Kirchner SK, Roeh A, Nolden J, Hasan A Diagnosis and treatment of schizotypal personality disorder: evidence from a systematic review NPJ Schizophr, 2018.PMID 30282970
  3. [3]Jakobsen KD, Skyum E, Hashemi N, Schjerning O, et al. Antipsychotic treatment of schizotypy and schizotypal personality disorder: a systematic review J Psychopharmacol, 2017.PMID 28347257
  4. [4]Gundersen KB, Arnfred B, Albert N, Rasmussen AR, et al. Treatment of schizotypal disorder: A systematic review and GRADE evaluation of the certainty of evidence Schizophr Res, 2026.PMID 41421074
  5. [5]Fusar-Poli P, Salazar de Pablo G, Correll CU, et al. Prevention of Psychosis: Advances in Detection, Prognosis, and Intervention JAMA Psychiatry, 2020.PMID 32159746